CN105166896A - Health-care food capable of improving memory in auxiliary manner - Google Patents
Health-care food capable of improving memory in auxiliary manner Download PDFInfo
- Publication number
- CN105166896A CN105166896A CN201510558941.1A CN201510558941A CN105166896A CN 105166896 A CN105166896 A CN 105166896A CN 201510558941 A CN201510558941 A CN 201510558941A CN 105166896 A CN105166896 A CN 105166896A
- Authority
- CN
- China
- Prior art keywords
- extract
- taurine
- health
- curcumin
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015654 memory Effects 0.000 title abstract description 14
- 235000013305 food Nutrition 0.000 title abstract description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229960003080 taurine Drugs 0.000 claims abstract description 29
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 22
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 238000001291 vacuum drying Methods 0.000 claims abstract description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 58
- 235000012754 curcumin Nutrition 0.000 claims description 28
- 229940109262 curcumin Drugs 0.000 claims description 28
- 239000004148 curcumin Substances 0.000 claims description 28
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 27
- 206010039966 Senile dementia Diseases 0.000 claims description 11
- 235000013402 health food Nutrition 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002386 leaching Methods 0.000 claims description 6
- 230000006993 memory improvement Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000002351 wastewater Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 235000020985 whole grains Nutrition 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 3
- 241000218628 Ginkgo Species 0.000 claims 3
- 238000007796 conventional method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 244000194101 Ginkgo biloba Species 0.000 abstract description 19
- 244000163122 Curcuma domestica Species 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 5
- 235000003373 curcuma longa Nutrition 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 235000013976 turmeric Nutrition 0.000 abstract description 5
- 238000007689 inspection Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract 3
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 16
- 150000003254 radicals Chemical class 0.000 description 15
- 238000011160 research Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 230000032683 aging Effects 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 230000009267 minimal disease activity Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 210000005013 brain tissue Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229930182494 ginsenoside Natural products 0.000 description 8
- 229940089161 ginsenoside Drugs 0.000 description 8
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 229910052793 cadmium Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 229930193195 schizandrin Natural products 0.000 description 4
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 4
- 102000012440 Acetylcholinesterase Human genes 0.000 description 3
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 229940068052 ginkgo biloba extract Drugs 0.000 description 3
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000005882 cadmium poisoning Diseases 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 2
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229930184727 ginkgolide Natural products 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000007074 memory dysfunction Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- -1 oxygen radicals Chemical class 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000037322 slow-wave sleep Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010002023 Amyloidoses Diseases 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100188686 Danio rerio opn1sw2 gene Proteins 0.000 description 1
- 102100031414 EF-hand domain-containing protein D1 Human genes 0.000 description 1
- 102100031418 EF-hand domain-containing protein D2 Human genes 0.000 description 1
- 101150096151 EFHD1 gene Proteins 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 101000802344 Homo sapiens Zinc finger SWIM domain-containing protein 7 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101150089053 SWS2 gene Proteins 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000012683 free radical ring-opening polymerization Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940045613 taurine 1000 mg Drugs 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a health-care food capable of improving memory and preventing and treating an Alzheimer's disease and a preparation method of the health care food. Through quality standard inspection, dried fresh ginseng and Chinese magnoliavine fruits are selected for preparing alcohol extraction extractum, the alcohol extraction extractum is matched with ginkgo leaf alcohol extraction extractum, then through vacuum drying, dried extractum is obtained and screened, turmeric, taurine and microcrystalline cellulose are added to the screened dried extractum to be mixed into a mixture, and the mixture is pelletized and pressed into tablets. The health-care food disclosed by the invention is obtained by compounding medicinal and edible substances, is convenient to carry and use, and is obvious in effects.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of for Improving memory power, health food of senile dementia prevention and cure and preparation method thereof.
Background technology
Along with socio-economic development, people's living standard improve, human longevity is also more and more longer, and the geriatric disease that aging brings is also increasing, and the senile dementia especially based on insomnia forgetfulness causes the burden of individual, family and society.China is in the aging epoch at present, and the way actively found desirable prevention and improve senile dementia seems particularly urgent! Recent studies is thought, aging is the general performance of the various biochemical reaction of body, is that the many factors in inside and outside (environmental pollution, stress, heredity etc.) coefficient result relates to the low hypothesis of choline function, inflammation or immune hypothesis, gene mutation hypothesis, amyloid hypothesis, oxidative stress hypothesis, apoptosis hypothesis etc.Being with recent memory obstacle for main clinical manifestation generally, take senile plaque expelling, NFT as the Progressive symmetric erythrokeratodermia neurodegenerative disease of main pathological change.The oxyradical theory proposed by Harman for 1956 is relatively generally acknowledged at present.This theory is pointed out, in body, the moment produces free radical, but has again effective Free-radical ring opening polymerization (as superoxide dismutase etc.) simultaneously, makes interior free yl maintain normal level.With advancing age, this balance is destroyed gradually, causes the surplus of free radical.Excessive free radicals, by large biological molecules such as membranous structure and nucleic acid, protein and enzyme such as peroxidation attack cells film, mitochondrial membranes, causes the unrighted acid generation lipid peroxidation on cell membrane and mitochondrial membrane, produces MDA.These MDAs and catabolite thereof make nucleic acid and protein molecule generation cross-linked polymeric, cause DNA gene mutation or abnormal replication and biology enzyme vigor to decline further, finally cause cell function to be badly damaged so that old and feeble, dead.
We combine the genunie medicinal materials developmental research of Changbai Mountain, Jilin Province and healthy food material Improving memory functional study basis carried out in the past; adopt this province real estate 5 years sun-dried ginsengs, the fruit of Chinese magnoliavine; be equipped with ginkgo leaf, curcumin, taurine form the present invention; institute's prescription synthesizes and kidney and spleen invigorating from free radical in removing brain and promotion brain internal protein respectively; regulate central cholinergic system; the number of mechanisms such as neuroprotective cell are set out, and comprehensive function reaches Improving memory power, sleep and prevents the effect of senile dementia.Scientific formula is reasonable, safe and effective nontoxic, and effect relaxes, and avoids the toxic and side effect of similar drugs with function (as epiphysin etc.) and the drug dependence of Long-Time Service, and domesticly has no identical product.
Summary of the invention
Goal of the invention: a series of senile dementia symptoms brought for China's aging population, improving water flood and memory, and anti-oxidant, auxiliary adjustment of blood fat, vision protection and raising immunity; The problems such as the drug induced toxic and side effect meter drug dependence of Long-Time Service are avoided to provide a kind of for Improving memory power, health food of senile dementia prevention and cure and preparation method thereof.
Technical scheme of the present invention: select sun-dried ginseng 40 parts through quality standard inspection; 30 parts, the fruit of Chinese magnoliavine prepares alcohol-extracted extract, is equipped with ginkgo leaf 50 parts of the water extracted immersing pastes, then becomes dry extract to sieve through vacuum drying; add turmeric and each 5 parts of taurine, microcrystalline cellulose mixing granulation compressing tablet.
The present invention is a kind of health food composite by integration of drinking and medicinal herbs material, and be convenient for carrying and use, effectiveness comparison is obvious.
Detailed description of the invention
This prescription adopts large genunie medicinal materials of our province Changbai Mountain real estate: 5 years sun-dried ginsengs and the fruit of Chinese magnoliavine; be equipped with ginkgo leaf; curcumin; the raw materials such as taurine; there is for ageing populations's exploitation the health food of auxiliary improvement of memory power, obtaining certain social benefit simultaneously also for promoting that the exploitation of our province large-scale planting improves its added value with industrialized development.
Prepare sun-dried ginseng fruit of Chinese magnoliavine alcohol extracting cream: take the sun-dried ginseng in formula, 70% alcohol heating reflux that the fruit of Chinese magnoliavine adds 8 times amount extracts 2 times, each 2 hours, merge extract, filter with flame filter press; Filtrate recycling ethanol, obtains alcohol extracting thick medicinal extract I when surveying relative density 1.25-1.30 when being concentrated into 50 DEG C for subsequent use; After filter residue volatilizes ethanol and a ginkgo leaf lixiviate, the common decocting of filter residue extracts.
Prepare ginkgo leaf medicinal extract: check the ginkgo leaf raw material selected through quality standard, carry out crushing, rinsing process, to be then immersed in the purifying waste water of 10 times of quality 1 hour, to be heated to 100 DEG C with multi-function extractor, lixiviate 3 hours, 0.147mm is sieved filters to obtain a leaching liquor; In the filter residue that three kinds of raw materials merge, add purifying waste water of 8 times of quality again decoct lixiviate 2 times, each 2 hours, obtain secondary leaching liquor; It is 1.25-1.30, temperature 70-80 DEG C that twice leaching liquor merging is carried out being evaporated to relative density, and pressure 0.085Mpa, is condensed into thick medicinal extract II, relative density 1.25-1.30.
Thick medicinal extract I after concentrated, thick medicinal extract II are put drying under reduced pressure in vacuum drying chamber, drying condition (temperature is 70-80 DEG C, and vacuum is 0.085MPa) respectively, respectively dry extract I, dry extract II.Dried dry extract is put in Universalpulverizer respectively and pulverizes, cross 0.177mm sieve, obtain extract powder I, extract powder II, for subsequent use.
Mixing, to granulate: get the curcumin of extract powder I, extract powder II and formula ratio and taurine, microcrystalline cellulose and put in V-Mixer and mix about 20 minutes, uniform coloration to be mixed is consistent, obtains total mixed powder; Total mixed powder is put in Wet mixed granulating machine, adds 70% ethanol wet softwood, crosses 1.0mm sieve series grain, wet granular 70 DEG C of freeze-day with constant temperature dry (moisture is less than 5%), sieve whole grain, obtain dry particle after 1.0mm; Add formula dolomol in dry particle in V-Mixer, mix (incorporation time is about 10 minutes), obtain hybrid particles.
Compressing tablet: get the hybrid particles mixed, puts in rotary tablet machine, regulates pressure, sheet weight, is pressed into the circle element sheet that every sheet is 0.5g, then chooses wherein residual, scarce underproof plain sheet.
Dressing: the coating agent (Opadry) getting formula ratio, is mixed with the coating solution of 18% by purified water.Preheating coating pan, controls EAT about 70 DEG C, leaving air temp about 45 DEG C, be placed in coating pan by qualified plain sheet, start coating pan, adjustment gun traffic makes even spraying in the plain sheet surface of rotating, sheet bed tempertaure controls at about about 37 DEG C, observe plain sheet Gain weight at any time, to the 0.02g(5% that increases weight) stop spraying, continue drying after about 10 minutes with hot blast, dry up with cold wind again, take out, choose the coating tablet that dressing is defective, damaged, incomplete, obtain coating tablet.
Packaging: coating tablet oral stable medicinal polythene bottle with high density is bottled, 120 every bottle.Oral stable medicinal polythene bottle with high density meets the standard of YBB00122002.Label after bottling, mounted box, 1 bottle/box.
Inspection, warehouse-in: after external packing box, vanning, be carried out in accordance with regulations sampling inspection, during vanning, lot number should be correct, clear, proper.Often criticize after packaging terminates, the consumption of correct statistics finished product quantity and packaging material.Through after the assay was approved, put in storage in time.
Workshop environment cleanliness situation
This production environment and management all meet the requirement of health food production management codes and standards, and concrete production clean area cleanliness factor is 300,000 grades.
Table 1 formula for a product
The consumption of table 2 raw material and safe edible amount
Number 50 people tried out by the health food of this kind of auxiliary improvement of memory power, efficiently reaches more than 86%.
Scientific basis:
Sun-dried ginseng system araliaceae ginseng plant, mainly refers to " panax ginseng in jiljn " of our province, and cultivated area and output all account for 85% of the whole nation, account for 70% of the world.Also has " American Ginseng " three large kind of " Korean ginseng " of Korea, " Fructus Arctii " of Japan and Canadian and U.S. in addition.Ginseng is exactly medicinal and edible plant since ancient times, with after reinforce vital energy, multiple arteries and veins takes off admittedly, reinforces the spleen to benefit the lung, promotes the production of body fluid, calm the nerves.Record according on the ancient medical books such as Shennong's Herbal, " the main tonifying five zang organs of ginseng, peace spirit, determine soul, only palpitation with fear, except perverse trend, improving eyesight, happy intelligence development, for a long time take to make light of one's life by commiting suicide prolong life ", and modern medicine study also proves: ginseng is the plant keeping organism balance and normal condition, promotion and regulating action can be played to partes corporis humani position health.Chemical Constituents of Panax Ginseng comprises saponin(e, carbohydrate, protein, polypeptide, amino acid, vitamin etc.Most of pharmacologically active that ginseng shows is the effect of ginsenoside, and ginsenoside has antifatigue, delays senility, and regulates central nervous system, improves immunity of organisms, improves the effects such as cardiovascular and cerebrovascular blood supply insufficiency.Ginseng is containing 40 various of monomers (wherein ginsenoside Rb1 and Rg1 have the improvement result of highly significant to senile dementia).By the expression and the test of Morris water maze detecting p-secretase and PS-1, Fang Xin etc. find that ginseng can improve the ability of learning and memory of the senile dementia rat through alchlor modeling; The discovery such as Liu Ying ginsenoside Rg1 can also improve the mobility of old decline animal, and, there is obvious anti-ischemic effect in neuroprotective unit to nerve cell to a certain extent, and the brain increasing mouse weighs and cortex thickness, protection brain cell etc.Result is also had to show, ginsenoside both can suppress the generation of free radical, also can the damaging action of facedown radical pair tissue and cell, or direct scavenging free radicals, also can strengthen the function of the antioxidant system of body own, block the damaging action of free radical from multiple link.Zhang Jialin etc. show ginsenoside Rbl to antioxidase activity influence research in aged rats blood, Rgl all can significantly improve superoxide dismutase (SOD) and catalase (CAT) vigor, strengthen the ability of body defenses toxic oxygen radicals damage, there is antidotal effect.Wang Hongli etc. find when carrying out panaxoside anti aging effect effect experiment, oral ginsenoside 100mg/kgd makes SOD vigor in the exhausted mining areas skin caused by D mono-galactolipin, hydroxyproline content obviously raises, MDA (MDA) content significantly reduces, CAT in blood, glutathione peroxidase (GSH2Px) vigor significantly raises, promote the metabolism of cell, accelerate the synthesis of ageing skin nucleus and protein, increase SOD content and activity in skin simultaneously, play the anti-oxidant and effect of scavenging radical that it is powerful, reduce lipid peroxidation product as the deposition of MDA, recover the normal physiological function of cell, and panaxoside also can the fibroblastic activity of chafe, promote collagen synthesis, skin is made to be tending towards rejuvenation, thus delay skin aging process.Zhang Xinmu etc. on ginsenoside-Rb on the impact of hyperlipidemia rats blood lipid metabolism and the research of antioxidation thereof in find, ginsenoside-Rb can significantly improve the activity of SOD, reduce over lipid oxide (LPO) and metabolite MDA content thereof, delaying senility course.
Experiment has confirmed that the aging of brain function is the learning and memory dysfunction that the change of neurotransmitter and acceptor thereof causes.Early stage research finds that ginsenoside Rbl can promote the release of mediator, increases the content of Ach in central nervous system.
The immune organ atrophy gradually with advancing age of body, function fails gradually, and the resistivity of pathogen obviously weakens to external world, is also one of reason of aging.Jiang Biwu etc. report that the humoral immunity of Ginsenoside on mice and cellular immunity all have spread effect, reticuloendothelial system phagocytic function can be made to strengthen, enhancing antibody is formed, increase the content of haematogenic immunity globulin, and the lymphocytic transformation function of the elderly can be stimulated, increase the synthesis of bone marrow cell DNA, RNA and protein.
Under cell cycle regulating, the cell ageing of multifactor participation is the basis of body aging, and its key feature is cell cycle arrest.The research such as Zhao Chaohui finds that ginsenoside Rgl can, by raising the expression of CyclinE and CDK2, make cell enter the S phase and play the effect of its anti-cell aging.Jin Jiansheng etc. adopt immunoblot assay to draw, and Rgl can play the WI 1 cell ageing effect of its anti-t-BHP induction by the expression of change Cell cycle regulatory proteins.
The fruit of Chinese magnoliavine is the dry mature fruit of magnoliaceae schisandra Schisandrachinensis (Turcz.) Baill, and taste is sour, sweet; Return lung, the heart, kidney channel.There is convergence astringent or styptic treatment for spontaneous sweating, nourishing generate fluid, effect of kidney calming.Modern study shows, and the suitable dosage fruit of Chinese magnoliavine can be increased work efficiency, and has good effect to improving neurasthenia insomnia.The fruit of Chinese magnoliavine contains the materials such as schizandrin (schizandrin), schizandrin A, deoxyschizandrin.Schizandrin can improve the intellection of people, strengthens the flexibility of brain excitement and process of inhibition, impels two processes to tend to balance.Lin Wei etc. by animal experiment find the fruit of Chinese magnoliavine can obviously extend mouse yellow Jackets induction the length of one's sleep, shorten barbital sodium induction mice sleep incubation period thus improve mice sleep.Huang Lili etc. can extend normal rat total sleep time (totalsleeptime by animal experiment schisandra fruit decoction of reaching a conclusion, TST), sleep phases shows as obvious prolong rats slow wave sleep II phase (slowwavesleep2, SWS2), to slow wave sleep I phase (slowwavesleep1, SWS1) and fast wave sleep (fastwavesleep, FWS) without impact.Test with healthy young man, within five minutes, threading enters pin, listens the rate of correcting errors of transmiter or long distance race to be index, takes schizandrin 5mg, these needs are concentrated one's energy, fine tune action, flexibility and endurance activity be all improved effect.
Ginkgo (Ginkgobiloba) deciduous tree, gymnosperm, have promoting blood circulation and removing blood stasis, remove obstruction in channels to relieve pain, astringe the lung and to relieving asthma, change effect of turbid lipopenicillinase, be dry fruit treasure in the world, the distinctive rare tree species of Ye Shi China, ginkgo leaf generally after frost occurs 2 ~ 3d gather and be advisable.Terpene in ginkgo leaf and flavones ingredient can downright bad, the scavenging free radicals of anti-cell peroxidating, anti-cell; flavones is by reducing blood viscosity; improve blood circulation; increase cerebral blood flow (CBF); improve cerebral oxygen supply, promote Brain circlulation, direct neuroprotective tissue; improve brain hypoxia-bearing capability and to ischemic brain tissue, there is protective effect, and being referred to as " understanding activator " or " understanding reinforcing agent ".Present pharmacological evaluation shows that it has and improves CBF, promotes brain blood flow and improves brain metabolism, as regulation of blood vessels agent; Significantly can improve the memory deficits in mice caused by natrium nitrosum and hyoscine, the memory improving adult mice keeps, and infers that its mechanism of action may be that flavones wherein and terpenoid regulate central cholinergic system, and scavenging free radicals.China is ginkgo native place, ginkgo biloba extract has more than 80% for export, the sixties in 20th century, Germany analyzes the composition of ginkgo leaf, find flavonoid substances in ginkgo leaf to animal circulating system, improve brain function and have good effect, from then on start the modern study of ginkgo leaf pharmacology and application.Popular the earliest be in the world the code name coming from Germany is the ginkgo biloba extract of EGB761, and it is the mixture of GINKGO BILOBA EXTRACT and ginkgoterpene lactone.Along with deepening continuously of research, occurred again that a code name is the ginkgolides mixture of BN52063 abroad, it is first medicine for clinical efficient platelet activating factor (PAF) antagonist.Nineteen ninety, in twice aging of brain new trend of holding in Singapore and Malaysia and the academic conference for the treatment of cerebral ischemia, France and Germany scientist describe ginkgo biloba p.e to be had and delays cell senescence, anti-ageing, the health-care efficacy of preventing and treating person in middle and old age's brain function deficiency.And the quality requirement proposed ginkgo biloba p.e: flavonoid glycoside >24%, ginkgolides >6%, ginkgo folic acid <5mg/kg.
The HPLC method specified by Pharmacopoeia of People's Republic of China version in 2005 annex VI D measures the general flavone in ginkgo biloba p.e.
Curcumin (curcumin) is a kind of yellow acid aldehydes matter, and be a kind of active component of turmeric, turmeric is Zingiber curcuma, is a herb that China commonly uses.Its active component, the history be employed was more than more than 6000.All the time, in the traditional medicine of India and China, all think that the promoting the circulation of qi of curcumin energy, expelling parasite, loose wind are invigorated blood circulation, inducing meastruation to relieve menalgia etc., there is good medical care effect.After 1970; the domestic and international pharmacological action about curcumin and biologically active have had a lot of research reports; curcumin has very strong anti-inflammatory activity, removes free radical and Interference fit effect, cancer suppressing action, antimutagenic effect, resisting HIV (HIV) effect and to multiple effects such as the synthesis of the protective effect of ischemic brain damage and liver kidney, anti-fibrosis effect, anti-Leishmania effect, reducing blood lipid, suppression prostaglandin and Antiaggregating activity on platelet.Wherein, curcumin may be mainly concerned with the following aspects to the effect of AD: macrophages phagocytic capacity is strengthened, and supports that immune system removes amyloid; Give the curcumin of low dose of curcumin than heavy dose of in the neurodegeneration of antagonism AD for a long time more effective.Find in Alzheimer's disease (AD) zoopery, curcumin can reduce amyloidoses in the AD course of disease, the discoveries such as Khajavi, the Apoptosis that curcumin effectively can also reduce the toxic action because mutant accumulation produces and induce, thus on treatment heredity peripheral neuropathy, there is potential curative effect.
Curcumin has lipophilic characteristics, plays in its cell act on by cell membrane, and the curcumin of minimum dosage can affect the nerves the hyperplasia of colloid and differentiation, reduces the hyperplasia of astrocytes, increases the active and differentiation of oligodendroglia.Research display, after the oral curcumin of Tg2576APPSW transgenosis AD mouse, low dosage (0.016%) not only can reduce oxidative damage level and inflammatory cytokine levels in brain tissue; Significantly reduce astroglial cell marker-glial fibrillary acidic protein (glialfibrillaryacidicprotein, GFAP) simultaneously.Curcumin suppresses the activity of AP-I, transcription factor and suppresses the expression of the amyloid relevant with AD, namely realizes antioxidation by the formation of suppression free radical and generation.Research finds, before the ligation of rat medium sized artery, 2h gives the hypodermic injection of 500mg/kg curcuma oil, and 24h can make Infarction volume obviously reduce, and neurologic defect symptom improves and can eliminate response to oxidative stress.Rat single intravenous injection curcumin l ~ 2mg/kg after local cerebral ischemia or Reperfu-sion, obviously reduces Infarction volume, reduces case fatality rate and reduces the water content of brain tissue.Anti-oxidant and the anti-inflammatory property of curcumin, can alleviate oxidation and the AD symptom that causes of inflammation.The research of university of India confirms, curcumin obviously reduces lipid peroxidation and the lipofuscin deposition of normal aging generation, reduces the increase of hepatocuprein, Na-K-ATP enzyme.Curcumin and heavy metal interact as cadmium, lead, prevent the toxic action that these metals cause.Curcumin can be combined with the zinc of redox active metal as iron, copper and non-redox active effectively, thus the NF_K of induction produces.In addition, turmeric have and reduces cholesterol effect, forms and reduce the beneficial effect of gathering performance to AD of serum peroxide by suppressing cholesterol.There are some researches show, curcumin can improve the learning and memory impairment of the permanent caused by ligature of bilateral common carotid arteries, reduces the generation of free radical and reduces nerve cell death.
We study discovery, different modes of administration (point pretreatment, simultaneously give with and post processing group, with the administration of 200mg/kgd curcumin sodium carboxymethylcellulose suspension oral gavage, continuous 45 days) adopt Jumping test and step-through test method to observe curcumin to AD model mice Behavior Test, give the pretreated group of curcumin and simultaneously prolongation of latency all appears in processed group, errors number reduces, namely learning and memory function obviously improves (P<0.05); In Mice brain tissues, ChAT activity raises, and AChE activity reduces (P<0.05); Reduce over lipid oxide (LPO) and metabolite MDA content thereof, SOD activity is increased, effectively removes excessive free radical, significantly improve neuronic damage, brain tissue is escaped injury, thus improve ability of learning and memory.
Taurine (taurine), because being isolated name at first from fel bovis, is commonly called as taurine and Taurine.Taurine is a kind of Small molecular β-sulphur amino acid; it belongs to nonprotein amino acid, because do not have genetic codon, does not participate in the synthesis of protein; but closely related with the metabolism of cystine, cysteine, human body mainly relies on the taurine in pickuping food to meet body requirement.Taurine is active by strengthening brain tissue superoxide dismutase (SOD), improves scavenging activated oxygen ability, and as a kind of inhibitory neurotransmitter, in cerebral ischemia, has neuroprotection.Research find its regulating body normal physiological function, participate in generation of bile, increase cell membrane anti-oxidant, participate in calcium balance in vivo, regulate osmotic pressure, promote brain development, improve nerve conduction and improve learning and memory, resisting various chemical substance to effects such as the infringements of cell.Hwang etc. report that taurine can increase the content of cadmium in cadmium rats intoxicated ight soil, thus decrease the accumulation in body, obviously can reduce the content of GSH in liver simultaneously, and reduce the content of MDA.Research shows that taurine can reduce MDA, GSH content that cadmium poisoning causes mouse cardiac muscle, increases GSSG content simultaneously, protection mouse cardiac muscle oxidative damage.The research such as Ye Meng shows that taurine can increase Cd, Cu, Zn content in liver after cadmium poisoning, and Zn content increases the increase much larger than Cu content.
Taurine has different physiological roles, is the requisite a kind of nutrient of health.China's taurine is mainly used in medicine, although as nutrient additive for food progressively be familiar with by compatriots and acceptance, the amount of state's human consumption taurine is also considerably less.Main countries of the current world per capita year consumption taurine amount are roughly: Japanese 60g, U.S. 50g, Britain 34g, German 32g, Canadian 29g, French 26g, Korea S 19g, Indonesia 17g, Singapore 17g, and China is less than 0.2g.Taurine is still safer as a kind of health products, takes the goods that some contain taurine, for health care, still very desirable.2007 by the Ministry of Public Health be approved as new resource for food use material, it be nature uniquely with free state exist amino acid, be extensively present in algae and animal tissue cell, the content in marine animal is particularly abundant.Taurine, as a kind of nutrient of high-quality, should be utilized by compatriots better.
We carried out experiment in vivo and inquired into taurine causes learning and memory in rats damage antagonism to cadmium, and every day is gavage taurine 1000mg/kg and 750mg/kg respectively, continuous 4 weeks, Normal group and model group gavage every day distilled water.Utilize that Morris water maze is capable, step dow n test and darkness avoidance test detect impact on memory dysfunction.The mouse having detected memory capability is put to death immediately and gets brain tissue; measure MDA (MDA); glutathione peroxidase (GSH-Px), superoxide dismutase (SOD); measure acetylcholinesterase (AChE) in rat cerebral tissue; the nervous system associated biochemical indexs such as cholinacetyltranslase (ChAT), Primary Study taurine causes the protective effect of Mice brain tissues to cadmium.Final discovery gives AchE vigor and the obvious reduction of model group (P < 0.05) in rat cerebral tissue after the intervention of 1000mg/kg taurine, and ChAT vigor obviously raises (P < 0.05).Infer that taurine can by protection cholinergic system, strengthen cholinergic nerve meta function, make the ChAT of cholinergic neuron, Ach level increases, the damage of antagonism cholinergic neuron, thus the learning and remembering ability improving AD rat; After giving 1000mg/kg taurine in addition, the mouse space exploration time obviously shortens, and platform searching times reduces, and average latency obviously extends, and errors number reduces, and illustrates that taurine is significantly improved Spatial memory obstacle caused by acute dye cadmium.
Claims (3)
1. a preparation method for the health food of auxiliary improvement of memory power, is characterized in that concrete steps are as follows:
Adopt the Changbai Mountain genunie medicinal materials 5 years sun-dried ginsengs 40 parts meeting quality standard, 30 parts, the fruit of Chinese magnoliavine, is equipped with ginkgo leaf 50 parts, curcumin and each 5 parts of taurine,
1) sun-dried ginseng fruit of Chinese magnoliavine alcohol extracting cream: 70% alcohol heating reflux that formula ratio sun-dried ginseng, the fruit of Chinese magnoliavine add 8 times of quality extracts 2 times, each 2 hours, merges extract, filters with flame filter press; Filtrate recycling ethanol, obtains alcohol extracting thick medicinal extract I when surveying relative density 1.25-1.30 when being concentrated into 50 DEG C for subsequent use; After filter residue volatilizes ethanol and a ginkgo leaf lixiviate, the common decocting of filter residue extracts;
2)ginkgo leaf medicinal extract: formula ratio raw material crushing, rinsing, to be soaked in the purifying waste water of 10 times of quality 1 hour, be heated to 100 DEG C of lixiviates 3 hours, 0.147mm is sieved filters to obtain a leaching liquor;
3) add purifying waste water of 8 times of quality in the filter residue of three kinds of raw material merging more than and decoct lixiviate 2 times, each 2 hours, obtain secondary leaching liquor; It is 1.25-1.30 that twice leaching liquor merging is carried out being evaporated to relative density, and temperature 50 C becomes thick medicinal extract II;
4)thick medicinal extract I, II after concentrated is put drying under reduced pressure in vacuum drying chamber respectively, obtains dry extract I, II, put in Universalpulverizer respectively and pulverize, cross 0.177mm sieve, obtain extract powder I, II, for subsequent use;
5)mixing, granulation, compressing tablet, dressing: get the curcumin of extract powder I, II and formula ratio and taurine, microcrystalline cellulose and put in V-Mixer and mix about 20 minutes, uniform coloration to be mixed is consistent, obtains total mixed powder; Total mixed powder adds 70% ethanol and enters in Wet mixed granulating machine, 1.0mm sieve series grain, wet granular 70 DEG C of freeze-day with constant temperature dry to moisture and be less than 5%, sieve whole grain must do particle after crossing 1.0mm; Add formula dolomol in V-Mixer, mix, obtain hybrid particles, put in rotary tablet machine, be pressed into the circle element sheet that every sheet is 0.5g;
6) dressing, packaging: obtain coating tablet by conventional method, packs 120 slices/bottle, 500mg/ sheet, is 3 times/day, 2 pieces/times during use.
2. the health food of the auxiliary improvement of memory power prepared by method according to claim 1.
3. by method according to claim 1 prepare health food as the application of the health food of auxiliary improvement of memory power and senile dementia symptom aspect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510558941.1A CN105166896B (en) | 2015-09-06 | 2015-09-06 | A kind of health food of auxiliary improvement of memory power |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510558941.1A CN105166896B (en) | 2015-09-06 | 2015-09-06 | A kind of health food of auxiliary improvement of memory power |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105166896A true CN105166896A (en) | 2015-12-23 |
| CN105166896B CN105166896B (en) | 2017-12-05 |
Family
ID=54889739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510558941.1A Active CN105166896B (en) | 2015-09-06 | 2015-09-06 | A kind of health food of auxiliary improvement of memory power |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105166896B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800007640A1 (en) * | 2018-07-30 | 2020-01-30 | Df Medica Oone Srl | COMPOSITION TO PREVENT OR TREAT FORMS OF COGNITIVE DECLINE |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1840143A (en) * | 2006-01-12 | 2006-10-04 | 湖南福湘生物技术有限公司 | Composite preparation for resisting oxidation, preventing and treating senile dementia and preparation method thereof |
| CN101019842A (en) * | 2007-03-09 | 2007-08-22 | 暨南大学 | Application of curcumin in preparing medicine for treating IIIV-1 relevant cognitive disorder |
| KR20070105679A (en) * | 2006-04-27 | 2007-10-31 | 한국과학기술연구원 | A composition for improving memory |
| CN101168025A (en) * | 2007-10-25 | 2008-04-30 | 张占军 | Medicine composition for preventing and treating senile dementia |
| KR101179766B1 (en) * | 2009-06-16 | 2012-09-04 | 주식회사 제이비티 | enhance learning ability health food |
| CN102919851A (en) * | 2012-10-26 | 2013-02-13 | 中科乐仁（北京）科技发展有限公司 | Health-care food composition for assisting to improve memory and preparation method thereof |
| CN103054049A (en) * | 2013-01-04 | 2013-04-24 | 山东大学（威海） | Method for preparing compound ginseng granules added with taurine |
| CN103734734A (en) * | 2014-01-29 | 2014-04-23 | 中国人民解放军空军航空医学研究所 | Functional food capable of improving cognition and relieving fatigue |
| CN103800410A (en) * | 2014-01-15 | 2014-05-21 | 吉林大学 | Cultivated ginseng ethanol extract with function of improving studying memory |
| CN104137990A (en) * | 2014-07-31 | 2014-11-12 | 溧阳市天目湖保健品有限公司 | Health food for improving memory and preparation method thereof |
-
2015
- 2015-09-06 CN CN201510558941.1A patent/CN105166896B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1840143A (en) * | 2006-01-12 | 2006-10-04 | 湖南福湘生物技术有限公司 | Composite preparation for resisting oxidation, preventing and treating senile dementia and preparation method thereof |
| KR20070105679A (en) * | 2006-04-27 | 2007-10-31 | 한국과학기술연구원 | A composition for improving memory |
| CN101019842A (en) * | 2007-03-09 | 2007-08-22 | 暨南大学 | Application of curcumin in preparing medicine for treating IIIV-1 relevant cognitive disorder |
| CN101168025A (en) * | 2007-10-25 | 2008-04-30 | 张占军 | Medicine composition for preventing and treating senile dementia |
| KR101179766B1 (en) * | 2009-06-16 | 2012-09-04 | 주식회사 제이비티 | enhance learning ability health food |
| CN102919851A (en) * | 2012-10-26 | 2013-02-13 | 中科乐仁（北京）科技发展有限公司 | Health-care food composition for assisting to improve memory and preparation method thereof |
| CN103054049A (en) * | 2013-01-04 | 2013-04-24 | 山东大学（威海） | Method for preparing compound ginseng granules added with taurine |
| CN103800410A (en) * | 2014-01-15 | 2014-05-21 | 吉林大学 | Cultivated ginseng ethanol extract with function of improving studying memory |
| CN103734734A (en) * | 2014-01-29 | 2014-04-23 | 中国人民解放军空军航空医学研究所 | Functional food capable of improving cognition and relieving fatigue |
| CN104137990A (en) * | 2014-07-31 | 2014-11-12 | 溧阳市天目湖保健品有限公司 | Health food for improving memory and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 丛伟红 等: "人参、银杏叶提取物对PDAPPV717I转基因小鼠海马乙酰胆碱和单胺类神经递质水平的影响", 《中国中西医结合杂志》 * |
| 周金彩 等: "复方银杏叶口服液的制备与临床观察", 《中国医院药学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800007640A1 (en) * | 2018-07-30 | 2020-01-30 | Df Medica Oone Srl | COMPOSITION TO PREVENT OR TREAT FORMS OF COGNITIVE DECLINE |
| WO2020026132A1 (en) * | 2018-07-30 | 2020-02-06 | Df Medica Oone S.R.L. | Composition for preventing or treating cognitive decline forms |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105166896B (en) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
| WO2007020382A2 (en) | Plant-based medicament for the treatment of liver disease | |
| KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
| CN104323281B (en) | Aquo-composition of preserved egg and Poria cocos and its preparation method and application | |
| CN102640829B (en) | Tea paste with myocardial ischemia function improving function and preparation method of tea paste | |
| CN106107375A (en) | Folium Bambosae flavone extracts and prepares this Folium Bambosae flavone health promoting beverage and the method for beverage | |
| CN107519310B (en) | Improve Chinese medicine composition and preparation process that energy inhibits growth of tumour cell function | |
| CN102715322A (en) | Food skin nourishing tea granule | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN105166896B (en) | A kind of health food of auxiliary improvement of memory power | |
| CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| KR20180101460A (en) | Uses of Sisotanke Tubulosa Extract and Isoquateroside in the Protection of Muscle | |
| CN108355052B (en) | Medicine for treating leucopenia after radiotherapy and chemotherapy and preparation method and application thereof | |
| KR101167628B1 (en) | A composition comprising black ginseng for treating or preventing dementia and improving cognitive function | |
| CN102308989B (en) | Health care composition of formica rufa, grape and propolis extracts | |
| CN105055856B (en) | A kind of Tea Pigment Chinese medicine composition and its preparation method and application for treating cardiovascular and cerebrovascular disease | |
| CN104523985A (en) | Cordyceps health-preservation traditional Chinese medicine liquor and preparation method thereof | |
| Koyama | Bioactive foods and herbs in prevention and treatment of cardiovascular disease | |
| CN114931214B (en) | Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof | |
| CN103860761A (en) | Pharmaceutical composition with effects of improving immunity and resisting fatigue as well as preparation method and application of pharmaceutical composition | |
| CN108079275A (en) | A kind of health Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN102613350B (en) | Ginkgo biloba garlic and white tea composite particle beverage | |
| CN107308328A (en) | The anti-flake of lycium ruthenicum black hair | |
| CN106434176A (en) | Health wine functional to lower three highs and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |